The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?

Please Log In or Register to continue.

Release Date: April 01, 2021
Expiration Date: April 01, 2022

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

There has been an increasing interest in the potential for moving beyond three-drug combinations to improve the treatment of patients with multiple myeloma in the frontline setting. In this activity, Dr. Kumar discusses the rationale, decision making, and trials that explore four-drug combinations for patients with newly diagnosed multiple myeloma. He also explains the efficacy and toxicity burden of these regimens.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe recent clinical trial data evaluating novel four-drug combinations in the frontline setting in the treatment of myeloma
  • Discuss the role of MRD testing in trials investigating four-drug regimens and the impact to clinical practice
  • Identify treatment-emergent side effects associated with four-drug regimens and optimal management strategies to mitigate these toxicities

Agenda

The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice? – Shaji K. Kumar, MD

Instructions for Participation and Credit

This activity is eligible for credit through April 01, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Shaji K. Kumar, MD
Professor of Hematological Malignancies
Medical Director
Clinical Research Office
Mayo Clinic Cancer Center
Rochester, Minnesota

Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr. Kumar is a Consultant in the Division of Hematology and Mark and Judy Mullins Professor of Hematological Malignancies at Mayo Clinic in Rochester, Minnesota. He serves as Medical Director for the Mayo Clinic Cancer Center Clinical Research Office.

Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee and as Chair of the NCCN Multiple Myeloma Guidelines Panel. His research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.

Accreditation

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-016-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Shaji Kumar has received institutional payments for his role as a consultant and ad board participant from AbbVie Inc., Amgen Inc., AstraZeneca, Bristol-Myers Squibb Company, Genentech - A Member of the Roche Group, Janssen Pharmaceuticals, Inc., Kite Pharma, and Takeda Oncology. He has received honoraria for his role as a consultant/ad board participant from Oncopeptides, Beigene and Antegene Corporation. He has received research support for Mayo Clinic Cancer Center and served as the principal investigator for clinical trials from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, CARsgen Therapeutics, Genentech, Janssen, Kite, Merck & Co., Inc., Novartis AG, Takeda Oncology, and TeneoBio.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.

©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.